小纤维多神经病的科学进展与临床诊疗综述
本综述指出小纤维多神经病虽常见但常被漏诊,推荐通过小腿皮肤活检测量表皮神经纤维密度确认诊断。约49%被诊断为纤维肌痛的疾病实际由小纤维神经病引起,特发性病例中三分之一至半数可找到可治疗病因,儿童和年轻成人应尽早诊治以恢复生活轨迹。
要点
- 症状非特异,推荐皮肤活检测量表皮神经纤维密度确认诊断。
- 纤维肌痛患者中约49%实为小纤维神经病,需筛查可治病因。
- 儿童和年轻成人患者应尽早诊断治疗,部分病例免疫治疗可能有效。
核心结论
- 小纤维多神经病常被漏诊,及时诊断和治疗可改善预后,尤其在儿童和年轻成人中。
- 改善 contributory 条件可能允许神经再生、延缓进展并预防永久损害。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- 近期荟萃分析结论:小纤维神经病占被标记为纤维肌痛疾病的49%。
- 特发性小纤维疾病患者中,三分之一至半数可通过病史和血液检查找到可治疗病因。
- 儿童和年轻成人患者中小纤维神经病常与炎症或免疫异常相关。
关键数值与推荐
- 标准检测为测量3-mm PGP9.5免疫标记小腿皮肤活检中的表皮神经纤维密度。
- 可治疗的遗传病因包括法布里病、转甲状腺素蛋白和原发性系统性淀粉样变性、遗传性感觉自主神经病1型及离子通道突变。
- 免疫组化病理证据提示小纤维功能障碍和去神经支配参与多种症状,包括劳累后不适、体位性心动过速和功能性胃肠不适。
临床怎么用
- 症状非特异,应通过皮肤活检和自主神经功能检测确认诊断。
- 特发性病例首先通过病史和血液检查筛查可治疗病因,家族性和儿童病例进行基因检测。
- 对类似吉兰-巴雷综合征和慢性炎性脱髓鞘性多神经病时间模式的病例,可考虑皮质类固醇和免疫球蛋白治疗。
局限性
- 本文为综述,未报告系统检索策略和纳入标准。
- 部分证据为初步性,如自身反应性参与的证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Small-fiber polyneuropathy involves preferential damage to the thinly myelinated A-delta fibers, unmyelinated C sensory fibers, or autonomic or trophic fibers. Although this condition is common, most patients still remain undiagnosed and untreated because of lagging medical and public awareness of research advances. Chronic bilateral neuropathic pain, fatigue, and nausea are cardinal symptoms that can cause disability and dependence, including pain medication dependence. OBSERVATIONS: Biomarker confirmation is recommended, given the nonspecificity of symptoms. The standard test involves measuring epidermal neurite density within a 3-mm protein gene product 9.5 (PGP9.5)-immunolabeled lower-leg skin biopsy. Biopsies and autonomic function testing confirm that small-fiber neuropathy not uncommonly affects otherwise healthy children and young adults, in whom it is often associated with inflammation or dysimmunity. A recent meta-analysis concluded that small-fiber neuropathy underlies 49% of illnesses labeled as fibromyalgia. Initially, patients with idiopathic small-fiber disorders should be screened by medical history and blood tests for potentially treatable causes, which are identifiable in one-third to one-half of patients. Then, secondary genetic testing is particularly important for familial and childhood cases. Treatable genetic causes include Fabry disease, transthyretin and primary systemic amyloidosis, hereditary sensory autonomic neuropathy-1, and ion-channel mutations. Immunohistopathologic evidence suggests that small-fiber dysfunction and denervation, especially of blood vessels, contributes to diverse symptoms, including postexertional malaise, postural orthostatic tachycardia, and functional gastrointestinal distress. Preliminary evidence implicates acute or chronic autoreactivity in some cases, particularly in female patients and otherwise healthy children and young adults. Different temporal patterns akin to Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy have been described; here, corticosteroids and immunoglobulins, which are often efficacious for inflammatory neuropathic conditions, are increasingly considered. CONCLUSIONS AND RELEVANCE: Because small fibers normally grow throughout life, improving contributory conditions may permit regrowth, slow progression, and prevent permanent damage. The prognosis is often hopeful for improving quality of life and sometimes for abatement or resolution, particularly in the young and otherwise healthy individuals. Examples include diabetic, infectious, toxic, genetic, and inflammatory causes. The current standard of care requires prompt diagnosis and treatment, particularly in children and young adults, to restore life trajectory. Consensus diagnostic and tracking metrics should be established to facilitate treatment trials.
引用
- Oaklander AL, Nolano M. Scientific Advances in and Clinical Approaches to Small-Fiber Polyneuropathy: A Review. JAMA Neurol. 2019. PMID: 31498378. doi:10.1001/jamaneurol.2019.2917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。